FDA has approved Gilead Science’s hepatitis B virus (HBV) drug Vemlidy for patients aged 12 and above. During clinical trials, the drug showed a reduction in DNA levels in 21% of patients. HBV, if not treated early, can cause cancer in later life. Gilead Science focuses sharply on HBV treatment drugs, and this is an important source of their revenue. The third quarter saw 70% growth in sales. Vemlidy is the hallmark of the company, and its sales are growing at a speed of 10% every year. The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver have also endorsed the use of Vemlidy for HBV treatment.
Read More from FiercePharma
